Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Instituto do Cancer do Estado de São Paulo
Fudan University
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Endeavor Biomedicines, Inc.
University Hospital, Lille
Dana-Farber Cancer Institute
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
Brigham and Women's Hospital
Merck Sharp & Dohme LLC
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Azienda USL Reggio Emilia - IRCCS
University Hospital Southampton NHS Foundation Trust
University of Chicago
SOLTI Breast Cancer Research Group
Gruppo Oncologico Italiano di Ricerca Clinica
Ain Shams University
Oslo University Hospital
Verastem, Inc.
University of Chicago
University of Florida
Bayer
PrECOG, LLC.
Eastern Cooperative Oncology Group
University of Turin, Italy
M.D. Anderson Cancer Center
Baylor College of Medicine
University of Calgary
National Institutes of Health Clinical Center (CC)
Wales Cancer Trials Unit
Swiss Cancer Institute
Epizyme, Inc.
National Institutes of Health Clinical Center (CC)
Intergroupe Francophone de Cancerologie Thoracique
Bayer
University of Texas Southwestern Medical Center
Mario Negri Institute for Pharmacological Research
National Institutes of Health Clinical Center (CC)
Columbia University
Mayo Clinic
Novartis
Bay Area Gynecology Oncology
Stanford University
University of Alabama at Birmingham